Skip to main content
Medical information Clinical review pending

Genetic Testing

Cancer Targeted Gene Panel Gastrointestinal Stromal Tumor GIST Test

Genetic test to identify mutations in genes associated with Gastrointestinal Stromal Tumors (GIST), aiding in diagnosis and personalized treatment planning.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question
Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample
Formalin-fixed paraffin-embedded (FFPE) tissue block from the tumor.
Results
Reports are typically available within 10 working days, provided the sample is submitted by Tuesday at 9 AM. Confirm with the laboratory before booking.
Preparation
Ensure the tissue block is properly labeled and accompanied by a completed NGS Test Requisition Form (Form 40). Ship at room temperature.
Test priceKSh 54,000

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the Cancer Targeted Gene Panel Gastrointestinal Stromal Tumor GIST Test test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

  • Insurer or scheme name & policy / member number
  • A clinician's request / prescription for the test
  • Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

+254

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

01

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

  • ✓Diagnosis of suspected Gastrointestinal Stromal Tumor (GIST).
  • ✓Personalized treatment planning for confirmed GIST.
  • ✓Identifying potential targeted therapy options.
  • ✓Understanding the genetic basis of a patient's GIST.
  • ✓Patients with symptoms suggestive of GIST (e.g., abdominal pain, bleeding).
02

In plain language

What this test helps you understand

This test helps identify specific genetic mutations driving GIST development, guiding personalized treatment decisions and potentially improving patient outcomes through targeted therapies.
The Cancer Targeted Gene Panel Gastrointestinal Stromal Tumor (GIST) Test is a specialized genetic analysis designed to detect specific mutations linked to the development of GISTs. These tumors originate from cells in the gastrointestinal tract. Identifying these genetic changes is vital for understanding the tumor's characteristics and guiding effective treatment strategies. This test analyzes key genes known to be involved in GIST development, including KIT, PDGFRA, BRAF, and others. Early detection and accurate genetic profiling can significantly improve patient outcomes by enabling targeted therapies. This test is recommended for individuals with suspected or confirmed GIST.
03

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →
04

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

1

Speak with us

We check the test and answer your questions before collection.

2

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

3

Understand your report

A counselor helps you understand the result and the next steps.

05

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →
PreparationEnsure the tissue block is properly labeled and accompanied by a completed NGS Test Requisition Form (Form 40). Ship at room temperature.
SampleFormalin-fixed paraffin-embedded (FFPE) tissue block from the tumor.
MethodologyNext-Generation Sequencing (NGS) is used to analyze the DNA extracted from the provided tissue sample for mutations in the targeted genes.
PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.
This test detects specific mutations within the targeted genes. It may not identify all possible genetic alterations associated with GIST. Results should be interpreted in conjunction with clinical findings and other diagnostic tests. Confirm with the laboratory before booking.
06

Read your report

What common result terms mean

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.
NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.
VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.
07

Questions people ask

Frequently asked questions

Gastrointestinal Stromal Tumor (GIST) is a rare type of cancer that starts in specialized cells in the wall of the gastrointestinal system.
Identifying specific gene mutations in a GIST helps doctors choose the most effective treatment, including targeted therapies.
A formalin-fixed paraffin-embedded (FFPE) tissue block from the tumor is required.
Results are typically available within 10 working days after sample receipt, assuming submission by the Tuesday deadline. Confirm with the laboratory before booking.
Your doctor will interpret the results in the context of your overall health and clinical situation to determine the best course of action.
Please call or WhatsApp us at +254711564616 to book the test.
08

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships
09

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

  • ACMG/AMP technical standards for sequence variant interpretation
  • ClinGen curation and gene–disease validity frameworks where applicable
  • LOINC-coded reporting for interoperable results
  • ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

  • Last updated: September 27, 2026
  • Medical review: not yet completed
  • Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →
Chat on WhatsApp